sorafenib has been researched along with Hyperthermia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpdemir, Ş; Bayram, C; Denkbaş, EB; Haberal, E; Kara, G; Vural, T | 1 |
| Han, X; Li, Z | 1 |
2 other study(ies) available for sorafenib and Hyperthermia
| Article | Year |
|---|---|
Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment.
Topics: Alginates; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Electron Spin Resonance Spectroscopy; Ferric Compounds; Hep G2 Cells; Humans; Hyperthermia; In Vitro Techniques; Light; Liver Neoplasms; Magnetics; Magnetite Nanoparticles; Metal Nanoparticles; Mice; Microspheres; Neoplasms; Particle Size; Powders; Scattering, Radiation; Sorafenib; Temperature; X-Ray Absorption Spectroscopy | 2020 |
Re: Chen S, Shi M, Shen L, et al. Microwave ablation versus sorafenib for intermediate-stage hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J hyperthermia 2020.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Hyperthermia; Liver Neoplasms; Microwaves; Propensity Score; Sorafenib | 2020 |